Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program

February 6, 2018

Responsive image

SAN FRANCISCO, Feb. 6, 2018 /PRNewswire/ — Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has selected an optimized cli…

Category: Precious Metals